menu
    • menu
    [{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"PF614","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Copernicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"DNA Nanoparticle-based Gene Therapy","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Achieve Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"TNX-1300","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Phoenix Pharmalabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"PPL-138","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Stalicla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Cessation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Gilgamesh Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Camino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"EpiVario","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":null,"graph2":null,"graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":null,"companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"}]

    Find Clinical Drug Pipeline Developments & Deals by National Institute on Drug Abuse

    Menu

    National Institute on Drug Abuse

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : EpiVario

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EpiVario Awarded SBIR Grant from NIH to Develop Treatments for Opioid Use Disorder

                            Details : The grant will be used to advance the company's research towards developing a novel epigenetic regulator as a treatment for opioid use disorder (OUD).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : EpiVario

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibogaine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Gilgamesh Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Gilgamesh Awarded $14M Grant for Cardiac-Safe Ibogaine Analog in Opioid Use Disorder

                            Details : The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for Opioid-Related Disorders.

                            Brand Name : GM-3009

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : Ibogaine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Gilgamesh Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naltrexone,Bupropion Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : BioCorRx

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BioCorRx Awarded $11M NIDA Grant for BICX104 Naltrexone Implant for MUD Treatment

                            Details : BioCorRx will focus funding on clinical development of BICX104 (naltrexone) in combination with Bupropion, currently in preclinical studies for methamphetamine use disorder.

                            Brand Name : BICX104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 28, 2024

                            Lead Product(s) : Naltrexone,Bupropion Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : BioCorRx

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBP-9330

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : Camino Pharma

                            Deal Size : $9.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            $9 Million NIH Grant Advances Drug to Treat Nicotine Addiction

                            Details : The net proceeds will fund longer toxicology studies and manufacturing of SBP-9330, a small molecule targeting mGlu2 receptor, to support planned Phase 2 trials for nicotine cessation.

                            Brand Name : SBP-9330

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 06, 2024

                            Lead Product(s) : SBP-9330

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : Camino Pharma

                            Deal Size : $9.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Recipient : Cessation Therapeutics

                            Deal Size : $14.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel ...

                            Details : The funding will support development of a subcutaneous formulation of its anti-fentanyl monoclonal antibody, CSX-1004 SQ, an investigational product that has successfully entered Phase 1 studies for the reversal of acute opioid over dose of fentanyl and ...

                            Brand Name : CSX-1004

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : CSX-1004

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Recipient : Cessation Therapeutics

                            Deal Size : $14.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Recipient : Tris Pharma Inc

                            Deal Size : $16.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance...

                            Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...

                            Brand Name : TRN-228

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 28, 2023

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Recipient : Tris Pharma Inc

                            Deal Size : $16.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STC-004

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : SiteOne Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor as Non-Opioid Therapeutic for Pain

                            Details : The funding will be used for the development of SiteOne's selective NaV1.8 inhibitor, STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.

                            Brand Name : STC-004

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : STC-004

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : SiteOne Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMS527

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : Omeros

                            Deal Size : $6.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addict...

                            Details : The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).

                            Brand Name : OMS527

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 10, 2023

                            Lead Product(s) : OMS527

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : Omeros

                            Deal Size : $6.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Stalicla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse...

                            Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

                            Brand Name : STP7

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : Mavoglurant

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Stalicla

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Phoenix Pharmalabs

                            Deal Size : $8.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Phoenix PharmaLabs Awarded $8.7 Million Grant from NIDA to Study Compound for Treatment of Cocaine Use Disorde...

                            Details : Funding from the grant will support the study of company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD) and the cost of advancing PPL-138 through its remaining preclinical studies and through Phase 1 human clinical trials.

                            Brand Name : PPL-138

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 06, 2022

                            Lead Product(s) : PPL-138

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Phoenix Pharmalabs

                            Deal Size : $8.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth